United Therapeutics Corporation $UTHR Position Boosted by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC increased its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 26.8% during the second quarter, Holdings Channel reports. The firm owned 110,274 shares of the biotechnology company’s stock after purchasing an additional 23,280 shares during the period. Los Angeles Capital Management LLC’s holdings in United Therapeutics were worth $31,687,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Chung Wu Investment Group LLC bought a new stake in United Therapeutics during the second quarter worth approximately $29,000. SVB Wealth LLC acquired a new stake in shares of United Therapeutics during the 1st quarter valued at $32,000. Geneos Wealth Management Inc. boosted its stake in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 85 shares in the last quarter. Brooklyn Investment Group grew its holdings in shares of United Therapeutics by 103.2% in the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 98 shares during the last quarter. Finally, WPG Advisers LLC acquired a new stake in shares of United Therapeutics during the first quarter worth $60,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 21,000 shares of the company’s stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $436.09, for a total value of $9,157,890.00. Following the transaction, the chief financial officer directly owned 8,118 shares of the company’s stock, valued at $3,540,178.62. This represents a 72.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The SEC filing for this sale provides additional information. Insiders sold 412,935 shares of company stock worth $173,677,147 over the last ninety days. 10.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. HC Wainwright increased their price target on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Wells Fargo & Company raised their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Wednesday, October 29th. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research report on Wednesday, October 29th. Finally, UBS Group lifted their price objective on shares of United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $503.90.

United Therapeutics Price Performance

NASDAQ UTHR opened at $448.91 on Friday. The firm has a market capitalization of $19.33 billion, a price-to-earnings ratio of 17.01, a price-to-earnings-growth ratio of 4.96 and a beta of 0.77. The company has a 50 day simple moving average of $423.96 and a 200-day simple moving average of $343.91. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $479.50.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same quarter in the prior year, the business earned $6.39 EPS. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. On average, analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.